Knowledge  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
hereditary  ||| S:13 E:24 ||| JJ
renal  ||| S:24 E:30 ||| JJ
cancer  ||| S:30 E:37 ||| NN
syndromes ||| S:37 E:46 ||| NNS
:  ||| S:46 E:48 ||| :
a  ||| S:48 E:50 ||| DT
pending  ||| S:50 E:58 ||| JJ
issue  ||| S:58 E:64 ||| NN
for  ||| S:64 E:68 ||| IN
oncologists  ||| S:68 E:80 ||| JJ
Renal  ||| S:80 E:86 ||| JJ
cell  ||| S:86 E:91 ||| NN
cancer  ||| S:91 E:98 ||| NN
( ||| S:98 E:99 ||| -LRB-
RCC ||| S:99 E:102 ||| NNP
)  ||| S:102 E:104 ||| -RRB-
is  ||| S:104 E:107 ||| VBZ
a  ||| S:107 E:109 ||| DT
rare  ||| S:109 E:114 ||| JJ
disease  ||| S:114 E:122 ||| NN
that  ||| S:122 E:127 ||| IN
accounts  ||| S:127 E:136 ||| NNS
for  ||| S:136 E:140 ||| IN
2-3 ||| S:140 E:143 ||| CD
%  ||| S:143 E:145 ||| NN
of  ||| S:145 E:148 ||| IN
all  ||| S:148 E:152 ||| DT
solid  ||| S:152 E:158 ||| JJ
malignancies ||| S:158 E:170 ||| NN
.  ||| S:170 E:172 ||| .
Although  ||| S:172 E:181 ||| IN
its  ||| S:181 E:185 ||| PRP$
etiology  ||| S:185 E:194 ||| NN
is  ||| S:194 E:197 ||| VBZ
not  ||| S:197 E:201 ||| RB
known ||| S:201 E:206 ||| VBN
,  ||| S:206 E:208 ||| ,
approximately  ||| S:208 E:222 ||| RB
4 ||| S:222 E:223 ||| CD
%  ||| S:223 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
RCC  ||| S:228 E:232 ||| NNP
occurs  ||| S:232 E:239 ||| VBZ
in  ||| S:239 E:242 ||| IN
the  ||| S:242 E:246 ||| DT
context  ||| S:246 E:254 ||| NN
of  ||| S:254 E:257 ||| IN
complex  ||| S:257 E:265 ||| JJ
hereditary  ||| S:265 E:276 ||| JJ
syndromes  ||| S:276 E:286 ||| NN
in  ||| S:286 E:289 ||| IN
which  ||| S:289 E:295 ||| WDT
the  ||| S:295 E:299 ||| DT
kidney  ||| S:299 E:306 ||| NN
lesions  ||| S:306 E:314 ||| NNS
are  ||| S:314 E:318 ||| VBP
associated  ||| S:318 E:329 ||| VBN
with  ||| S:329 E:334 ||| IN
other  ||| S:334 E:340 ||| JJ
manifestations ||| S:340 E:354 ||| NNS
.  ||| S:354 E:356 ||| .
Therefore ||| S:356 E:365 ||| RB
,  ||| S:365 E:367 ||| ,
clinical  ||| S:367 E:376 ||| JJ
suspicion  ||| S:376 E:386 ||| NN
is  ||| S:386 E:389 ||| VBZ
essential  ||| S:389 E:399 ||| JJ
for  ||| S:399 E:403 ||| IN
proper  ||| S:403 E:410 ||| JJ
diagnosis  ||| S:410 E:420 ||| NN
and  ||| S:420 E:424 ||| CC
management ||| S:424 E:434 ||| NN
.  ||| S:434 E:436 ||| .
In  ||| S:436 E:439 ||| IN
this  ||| S:439 E:444 ||| DT
review  ||| S:444 E:451 ||| NN
a  ||| S:451 E:453 ||| DT
practical  ||| S:453 E:463 ||| JJ
summary  ||| S:463 E:471 ||| NN
to  ||| S:471 E:474 ||| TO
aid  ||| S:474 E:478 ||| VB
treating  ||| S:478 E:487 ||| VBG
physicians  ||| S:487 E:498 ||| NNS
in  ||| S:498 E:501 ||| IN
the  ||| S:501 E:505 ||| DT
identification  ||| S:505 E:520 ||| NN
of  ||| S:520 E:523 ||| IN
hereditary  ||| S:523 E:534 ||| FW
RCC  ||| S:534 E:538 ||| FW
syndromes ||| S:538 E:547 ||| FW
,  ||| S:547 E:549 ||| ,
including  ||| S:549 E:559 ||| VBG
von  ||| S:559 E:563 ||| JJ
Hippel-Lindau  ||| S:563 E:577 ||| JJ
syndrome ||| S:577 E:585 ||| NN
,  ||| S:585 E:587 ||| ,
hereditary  ||| S:587 E:598 ||| FW
papillary  ||| S:598 E:608 ||| FW
RCC ||| S:608 E:611 ||| NNP
,  ||| S:611 E:613 ||| ,
Birt-Hogg-Dub√©  ||| S:613 E:628 ||| JJ
syndrome ||| S:628 E:636 ||| NN
,  ||| S:636 E:638 ||| ,
and  ||| S:638 E:642 ||| CC
hereditary  ||| S:642 E:653 ||| JJ
leiomyomatosis  ||| S:653 E:668 ||| JJ
RCC ||| S:668 E:671 ||| NNP
,  ||| S:671 E:673 ||| ,
is  ||| S:673 E:676 ||| VBZ
provided ||| S:676 E:684 ||| VBN
.  ||| S:684 E:686 ||| .
Early  ||| S:686 E:692 ||| JJ
recognition  ||| S:692 E:704 ||| NN
of  ||| S:704 E:707 ||| IN
these  ||| S:707 E:713 ||| DT
specific  ||| S:713 E:722 ||| JJ
populations  ||| S:722 E:734 ||| NNS
will  ||| S:734 E:739 ||| MD
lead  ||| S:739 E:744 ||| VB
to  ||| S:744 E:747 ||| TO
better  ||| S:747 E:754 ||| JJR
care ||| S:754 E:758 ||| NN
,  ||| S:758 E:760 ||| ,
correct  ||| S:760 E:768 ||| JJ
surveillance ||| S:768 E:780 ||| NN
,  ||| S:780 E:782 ||| ,
and ||| S:782 E:785 ||| CC
,  ||| S:785 E:787 ||| ,
in  ||| S:787 E:790 ||| IN
the  ||| S:790 E:794 ||| DT
near  ||| S:794 E:799 ||| JJ
future ||| S:799 E:805 ||| NN
,  ||| S:805 E:807 ||| ,
to  ||| S:807 E:810 ||| TO
personalized  ||| S:810 E:823 ||| VB
treatment  ||| S:823 E:833 ||| NN
taking  ||| S:833 E:840 ||| VBG
advantage  ||| S:840 E:850 ||| NN
of  ||| S:850 E:853 ||| IN
underlying  ||| S:853 E:864 ||| VBG
genetic  ||| S:864 E:872 ||| JJ
defects ||| S:872 E:879 ||| NNS
.  ||| S:879 E:881 ||| .
